Segura MJG, Ríos RG, Blanco LA

Language: Spanish
References: 21
Page: 80-85
PDF size: 121.33 Kb.

ABSTRACT

The treatment of patients with osteogenesis imperfecta through the administration of bisphosphonates has been shown to improve the rate of bone mineralization assessed by densitometry, as well as the decrease in fracture episodes during the first year of treatment. The primary objective of this study is to demonstrate the effectiveness of the different bisphosphonates that have been administered in patients with. Material and methods: A cross-sectional study of patients with OI assessed and treated by the use of bisphosphonates in a period between March 2004 and November 2015. Different variables such as gender, age, type of OI according to the classification of Sillence, type of bisphosphonate, treatment time, bone mineral density, number of fractures and homeostasis of calcium, phosphate, alkaline phosphatase, among others, were subjected to statistical evaluation by paired t test. All the data were collected and submitted to study using the SPSS 2^® system. Results: Three study groups were defined according to the type of bisphosphonate used. It was observed that patients treated with Zolendronic acid significantly increased bone mineralization (p ‹ 0.001) and significantly reduced the episodes of fractures during the first year of treatment (p ‹ 0.001) with respect to patients treated with risendronate and alendronate, respectively. Conclusions: Patients with osteogenesis imperfecta treated by the administration of bisphosphonates have been shown to improve bone mineral density and decrease the recurrence of fractures. It was determined that the efficacy of zolendronic acid was superior to that shown by both risendronate and alendronate. This will help to determine more effective treatment plans in the medium and long term for patients with OI.

REFERENCES

1. Huang RP, Ambrose CG, Sullivan E, Haynes RJ. Functional significance of bone density measurements in children with osteogenesis imperfecta. J Bone Joint Surg Am. 2006; 88(6): 1324-1330.

2. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7(9): 540-557.

3. Sillence DO, Senn A, Danks DM. Genetic hetrogeneity in osteogenesis imperfecta. J Med Genet. 1979; 16(2): 101-116.

4. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000; 15: 1650-1658.

5. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002; 17(1): 30-38.

6. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L et al. Osteogenesis imperfecta type VII: an Autosomal recesive form of Brittle bone disease. Bone. 2002; 31(1): 12-18.

7. Labuda M, Morissette J, Ward LM, Rauch F, Lalic L, Roughley PJ et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone. 2002; 31(1): 19-25.

8. Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993; 8(10): 1227-1233.

9. Zionts LE, Nash JP, Rude R, Ross T, Stott NS. Bone mineral density in children with mild osteogenesis imperfecta. J Bone Joint Surg Br. 1995; 77(1): 143-147.

10. Cepollaro C, Gonnelli S, Pondrelli C, Montagnani A, Martini S, Bruni D et al. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. Calcif Tissue Int. 1999; 65(2): 129-132.

11. Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004; 34(3): 539-546.

12. Urgery S, Ncorporated I, Density B. Efficacy of alendronate in the treatment of low. J Bone Joint Surg Am. 2012; 62(1): 1-6.

13. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med. 1995; 333(22): 1437-1443.

14. Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333:1437-43.

15. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007; 4: CD005324.

16. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002; 141(5): 644-651.

17. Castillo H, Samson-Fang L; American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009; 51(1): 17-29.

18. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006; 21(1): 132-140.

19. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009; 24(7): 1282-1289.

20. Glorieux FH, Bishop N, Bober M, Brain CE, Devogelaer J. et al. Intravenous zoledronic acid (ZOL) compared to intravenous pamidronate in children with severe osteogenesis imperfect (OI). Calcified Tissue International. 2008; 82: S85-S85.

21. Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Saffety and efficacy of a year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012; 25(5-6): 485-491.